Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$39.54M$39.54M+24.7% vs Q3 2020 Net Income$558.00K$558.00KN/M vs Q3 2020 EPS Diluted$0.04$0.04N/M vs Q3 2020 Gross Profit$23,023,000+32.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,062,000−64.8% Free Cash Flowderived$778,000−86.1% Margins · derivedGross margin58.2%+3.5 pt vs Q3 2020
Operating margin3.3%+28.3 pt vs Q3 2020
Net margin1.4%+21.6 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 5, 2021 · 36 d after period end